



TITAN BIOTECH LTD.

AN ISO 9001:2015 CERTIFIED COMPANY



Office : 903-909, 9th Floor, Bigjos Tower, Netaji Subhash Place, Delhi-110034, India
Tel. : 011-27355742, 71239900 (44 Lines) | Fax : +91-11-47619811 | CIN: L74999RJ1992PLC013387

To,

14.11.2022

Corporate Services Department,
BSE Ltd.,
Phiroze Jeejeebhoy Tower,
Dalal Street,
Mumbai- 400001

Dear Sir,

Sub: Outcome Of Board Meeting

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors, at its meeting held today i.e. **Monday, 14th November, 2022, at 903-909, 9th Floor, Bigjos Tower, Netaji Subhash Place, Delhi-110034**, have inter-alia-

1. Approved the Standalone and Consolidated Unaudited Financial Results and Limited Review Report for the quarter ended 30th September, 2022.

In terms of the Provisions of Regulation 33 and of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing the following:

1. Unaudited Financial Results for the quarter ended 30th September, 2022.
2. Limited Review Report for the quarter ended 30th September, 2022.

The meeting of Board of Directors commenced at 03:00 P.M. and concluded at 03:30 P.M.

The above information will be available on the website of the Company i.e <https://titanbiotechltd.com>

This is for your kind information and record please.

Thanking you,
Yours faithfully,
For Titan Biotech Limited


Charanjit Singh
Company Secretary
Membership Number: A12726

R.O. & Works: Unit I: A-902 A, RIICO Industrial Area, Phase-III, Bhiwadi-301019, Rajasthan
Unit II: E-540, Industrial Area, Chopanki, Bhiwadi-301019, Rajasthan

E-mail: marketing@titanbiotechltd.com

Website: www.titanbiotechltd.com | www.titanmedia.in



A N S K & Associates

CHARTERED ACCOUNTANTS

**OFFICE : 414, RG Trade Tower, Netaji Subhash Place,
Pitampura, Delhi-110034**

OFFICE NO. 011-46010089

EMAIL :amccorporateservices@gmail.com

Independent Auditor's Review Report on Quarterly and year to date Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To,

THE BOARD OF DIRECTORS
TITAN BIOTECH LIMITED

1. We have reviewed the accompanying Statement of Standalone Unaudited Financial Results of Titan Biotech Limited (the "Company"), for the quarter ended September 30, 2022 and the year to date results for the period 1st April 2022 to 30 September 2022 (the "Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 and Regulation 52 read with Regulation 63(2) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 193 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



A N S K & Associates

CHARTERED ACCOUNTANTS

OFFICE : 414, RG Trade Tower, Netaji Subhash Place,
Pitampura, Delhi-110034

OFFICE NO. 011-46010089

EMAIL :amccorporateservices@gmail.com

4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 and Regulation 52 read with Regulation 63(2) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

5. Other Matter

The Statement includes comparative financial results of the Company for the corresponding quarter and half year ended September 30, 2021 and previous quarter ended June 30, 2022, which have been reviewed by the predecessor audit firm, where they have expressed an unmodified conclusion vide report dated November 12, 2021 and August 10, 2022 respectively. The Statement also includes financial results for the year ended March 31, 2022, which have been audited by the predecessor audit firm, where they have expressed an unmodified opinion vide report dated May 30, 2022.

Our conclusion is not modified in respect of this matter.

For A N S K & Associates

Chartered Accountants

Firm's Registration No. 026177N

Akhil
Mittal

Digitally signed
by Akhil Mittal
Date: 2022.11.14
15:07:50 +05'30'

(CA Akhil Mittal)

Partner

M.No. 517856

Date: 14.11.2022

Place: New Delhi

UDIN: **22517856BDAUPT3961**



A N S K & Associates

CHARTERED ACCOUNTANTS

**OFFICE : 414, RG Trade Tower, Netaji Subhash Place,
Pitampura, Delhi-110034**

OFFICE NO. 011-46010089

EMAIL :amccorporateservices@gmail.com

Independent Auditor's Review Report on Quarterly and Year to date Unaudited Consolidated Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To,

THE BOARD OF DIRECTORS
TITAN BIOTECH LIMITED

1. We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of Titan Biotech Limited (the "Company") and its Associates, for the quarter ended September 30, 2022 and the consolidated year to date results for the period from 1 April 2022 to 30 September 2022 (the "Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 and Regulation 52 read with Regulation 63(2) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This Statement, which is the responsibility of the Holding Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 193 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



A N S K & Associates

CHARTERED ACCOUNTANTS

OFFICE : 414, RG Trade Tower, Netaji Subhash Place,
Pitampura, Delhi-110034

OFFICE NO. 011-46010089

EMAIL :amccorporateservices@gmail.com

-
4. The Statement includes results of the Holding Company -Titan Biotech Limited and Associate Company - Peptech Biosciences Limited.
 5. The accompanying unaudited consolidated financial results includes unaudited interim financial results and other unaudited financial information in respect of its associates which have been approved and furnished to us by the management. Our Conclusion on the statement is not modified in respect of the above matter.
 6. Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 and Regulation 52 read with Regulation 63(2) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.
 7. The unaudited consolidated financial results also includes the Group's share of net profit after tax of Rs. 91.59 lacs and 220.81 lacs and total comprehensive income of Rs. 91.59 Lacs and Rs. 220.81 lacs for the quarter and six month ended 30th September 2022, respectively, as considered in the consolidated unaudited financial results, in respect of one Associate, based on their interim financial results which have not been reviewed/audited by their Auditor. Our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of a associate, are based solely on such unaudited interim financial results. According to the information and explanations given to us by the management, these interim financial results are not material to the Group.
Our conclusion is not modified in respect of this matter.

8. Other Matter

The Statement includes comparative consolidated financial results of the Company for the corresponding quarter and half year ended September 30, 2021 and previous quarter ended June 30, 2022, which have been reviewed by the predecessor audit firm, where they have expressed an unmodified conclusion vide report dated November 12, 2021 and August 10, 2022 respectively. The Statement also includes financial results for the year ended March 31, 2022, which have been audited by the predecessor audit firm, where they have expressed an unmodified opinion vide report dated May 30, 2022.

Our conclusion is not modified in respect of this matter.



A N S K & Associates

CHARTERED ACCOUNTANTS

OFFICE : 414, RG Trade Tower, Netaji Subhash Place,
Pitampura, Delhi-110034

OFFICE NO. 011-46010089

EMAIL :amccorporateservices@gmail.com

For A N S K & Associates

Chartered Accountants

Firm's Registration No. 026177N

Akhil
Mittal

Digitally signed
by Akhil Mittal
Date: 2022.11.14
15:06:59 +05'30'

(CA Akhil Mittal)

Partner

M.No. 517856

Date: 14.11.2022

Place: New Delhi

UDIN: **22517856BDAZSI4426**

TITAN BIOTECH LIMITED

Regd. Office :- A-902 A, RIICO Industrial Area, Phase III, Bhiwadi, Rajasthan-301019

Phone No. 011- 71239900, Email : hrd@titanbiotechltd.com www.titanbiotechltd.com CIN : L74999RJ1992PLC013387

STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND SIX MONTHS ENDED ON 30TH SEPTEMBER, 2022

(Rs. IN LAKHS) except for EPS


Sr. No	PARTICULARS	STANDALONE					
		QUARTER ENDED			SIX MONTHS ENDED		YEAR ENDED
		30.09.2022 UNAUDITED	30.06.2022 UNAUDITED	30.09.2021 UNAUDITED	30.09.2022 UNAUDITED	30.09.2021 UNAUDITED	31.03.2022 AUDITED
1	INCOME						
	Revenue from operations	4,183.38	3,499.62	3,063.05	7,683.00	6,349.34	12,354.89
	Other Income	85.64	31.64	24.76	117.28	37.18	94.13
	Total Income	4,269.02	3,531.26	3,087.81	7,800.28	6,386.52	12,449.02
2	EXPENSES						
	Cost of Materials Consumed	2,178.59	1,784.39	1,475.15	3,962.98	2,966.70	5,912.24
	Changes in inventories of Finished Goods, Stock-in-Trade and Work-in-Progress	(44.93)	(60.73)	61.16	(105.66)	67.97	(17.30)
	Employee Benefit Expenses	452.21	379.95	348.30	832.16	661.90	1,433.00
	Finance Costs	17.03	17.59	19.09	34.62	43.07	78.39
	Depreciation and Amortization Expenses	63.76	60.45	55.44	124.21	110.48	236.91
	Other Expenses	549.38	589.37	501.22	1,138.75	872.65	1,908.88
	Total Expenses	3,216.04	2,771.02	2,460.36	5,987.06	4,722.77	9,552.12
3	Profit/(loss) before exceptional items and tax (1-2)	1,052.98	760.24	627.45	1,813.22	1,663.75	2,896.90
4	Exceptional Items	-	-	-	-	-	-
5	Profit/ (loss) before tax (3+4)	1,052.98	760.24	627.45	1,813.22	1,663.75	2,896.90
6	Tax expense:						
	I) Current Tax	268.61	181.86	124.02	450.47	414.45	735.07
	II) Deferred Tax	(2.41)	0.65	2.03	(1.76)	3.92	(6.57)
	(III) Earlier year taxes	(3.43)	-	-	(3.43)	0.00	(0.03)
	Total Tax (I+II)	262.77	182.51	126.05	445.28	418.37	728.47
7	Profit (Loss) for the period after Tax (5-6)	790.21	577.73	501.40	1,367.94	1,245.38	2,168.43
8	Other comprehensive income (Net of Tax)						
A.	Items that will not be reclassified to profit or loss						
	Re-measurement gain on defined benefit plans	-	-	-	-	-	(2.08)
B	(i) Items that will be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
	Total Other Comprehensive Income for the period (A+B)(net of taxes)	-	-	-	-	-	(2.08)
9	Total Comprehensive Income for the period (7+8)	790.21	577.73	501.40	1,367.94	1,245.38	2,166.35
10	Paid-up equity share capital (Face Value of Rs. 10/- each)	826.37	826.37	826.37	826.37	826.37	826.37
11	Other Equity	-	-	-	-	-	7,798.04
12	Earnings per equity share (face value of Rs. 10/- each) not annualised						
	(1) Basic	9.56	6.99	6.07	16.55	15.07	26.24
	(2) Diluted	9.56	6.99	6.07	16.55	15.07	26.24

Notes:

- The above unaudited standalone financial results for the quarter and six months ended on 30.09.2022 have been reviewed by the Audit Committee and taken on record by the Board of Directors of the Company at its meeting held on November 14, 2022. The Statutory Auditors of the Company have carried out a limited review in terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements), 2015.
- Previous period figures are regrouped/reclassified in line with the current period.
- The Company has only one reportable business segment.
- The Company has elected to exercise the option permitted under section 115BAA of the Income Tax Act, 1961 as introduced by Taxation Law (Amendment) Ordinance 2019. Accordingly, the Company has recognized provision for income tax for the quarter and six months ended on 30th Sept. 2022 and remeasured its deferred tax balance on the basis of the rate prescribed in the said section.
- The total sale for the quarter ended 30.09.2022 includes sale of Products of Rs. 11.29 Lakhs the demand for which arose due to Covid 19 Pandemic.
- The standalone unaudited financial results have been prepared in accordance with the Indian Accounting Standards ("Ind AS") specified in the Companies (Indian Accounting Standards) Rules 2015 (as amended) under section 133 of the Companies Act 2013 (the "accounting principles generally accepted in India").
- Freight amount has been added in revenue from operation for the purpose of calculation of sales including GST in current year. Freight also added in total in other expenses to neutralise the impact of its addition in revenue in current year.

For and on behalf of Board of Directors
for TITAN BIOTECH LIMITED

NARESH KUMAR SINGLA
Managing Director
DIN-00027448



Place : Delhi
Dated : 14.11.2022

TITAN BIOTECH LIMITED

Regd. Office :- A-902 A RIICO Industrial Area, Phase III, Bhiwadi, Rajasthan-301019

Phone No. 011- 71239900, Fax No. +91-11-47619811 Email : hrd@titanbiotechltd.com www.titanbiotechltd.com CIN : L74999RJ1992PLC013387

STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND SIX MONTHS ENDED ON 30TH SEPTEMBER, 2022

(Rs. IN LAKHS) except for EPS


Sr. No.	PARTICULARS	STANDALONE					
		QUARTER ENDED			SIX MONTHS ENDED		YEAR ENDED
		30.09.2022	30.06.2022	30.09.2021	30.09.2022	30.09.2021	31.03.2022
		UNAUDITED	UNAUDITED	UNAUDITED	UNAUDITED	UNAUDITED	AUDITED
1	Total Income from Operations (Net)	4,269.02	3,531.26	3,087.81	7,800.28	6,386.52	12,449.02
2	Net Profit/(Loss) for the period (before tax, exceptional and/or extraordinary items)	1,052.98	760.24	627.45	1,813.22	1,663.75	2,896.90
3	Net Profit/(Loss) for the period before tax (after exceptional and/or extraordinary items)	1,052.98	760.24	627.45	1,813.22	1,663.75	2,896.90
4	Net Profit/(Loss) for the period after tax (after exceptional and/or extraordinary items)	790.21	577.73	501.40	1,367.94	1,245.38	2,168.43
5	Total comprehensive income for the period (comprising Profit/(Loss) for the period(after tax) and Other Comprehensive income(after tax)(refer note 3)	790.21	577.73	501.40	1,367.94	1,245.38	2,166.35
6	Paid-up Equity Share Capital (Face value of Rs. 10/- per share)	826.37	826.37	826.37	826.37	826.37	826.37
7	Other Equity excluding Revaluation Reserves as per the balance sheet	-	-	-	-	-	7,798.04
8	Earning Per Share (of INR 10/- each)						
	(a) Basic	9.56	6.99	6.07	16.55	15.07	26.24
	(b) Diluted	9.56	6.99	6.07	16.55	15.07	26.24

NOTES :

- The above is an extract of the detailed format of standalone Unaudited Financial Results for the quarter and six months ended on 30.09.2022 filed with the BSE Limited Under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Standalone Unaudited Financial Results for the said quarter and six months ended on 30.09.2022 are available on the website of BSE Limited at www.bseindia.com and on company website at www.titanbiotechltd.com. The statutory auditors of the company have carried out a limited review of the aforesaid results.
- The above unaudited standalone financial results for the quarter and six months ended on 30.09.2022 have been reviewed by the Audit Committee and taken on record by the Board of Directors of the Company at its meeting held on November 14, 2022. The Statutory Auditors of the Company have carried out a limited review in terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements), 2015.
- The Company has elected to exercise the option permitted under section 115BAA of the Income Tax Act, 1961 as introduced by Taxation Law(Amendment) Ordinance 2019. Accordingly, the Company has recognized provision for income tax for the quarter and six months ended on 30th Sept. 2022 and remeasured its deferred tax balance on the basis of the rate prescribed in the said section.
- The total sale for the quarter ended 30.09.2022 includes sale of Products of Rs. 11.29 Lakhs the demand for which arose due to Covid 19 Pandemic.
- The standalone unaudited financial results have been prepared in accordance with the Indian Accounting Standards ('Ind AS') specified in the Companies (Indian Accounting Standards) Rules 2015 (as amended) under section 133 of the Companies Act 2013 (the "accounting principles generally accepted in India").
- Freight amount has been added in revenue from operation for the purpose of calculation of sales including GST in current year. Freight also added in total in other expenses to neutralise the impact of its addition in revenue in current year.

For and on behalf of Board of Directors
for TITAN BIOTECH LIMITED

NARESH KUMAR SINGLA
Managing Director
DIN-00027448



Place : Delhi
Dated : 14.11.2022


TITAN BIOTECH LIMITED
Standalone Balance Sheet as at 30th September, 2022

(Rs. in Lakhs.)



Particulars	As at	
	30/09/2022 Unaudited	31/03/2022 Audited
I ASSETS		
1. Non-Current Assets		
a. Property, Plant and Equipment	2,557.35	2,554.21
b. Capital Work-in-Progress	701.35	363.39
c. Right of use Assets	914.14	933.84
d. Intangible assets	9.92	10.46
e. Financial Assets		
(i) Investments	678.75	403.12
(ii) Other Financial Assets	169.69	168.54
Total Non-current assets	5,031.20	4,433.56
2. Current Assets		
a. Inventories	3,980.12	3,467.97
b. Financial Assets		
(i) Trade receivables	2,534.45	1,635.91
(ii) Cash and cash equivalents	347.03	681.39
c. Current Tax Assets (Net)	-	-
d. Other Current Assets	183.76	537.36
Total Current assets	7,045.36	6,322.63
TOTAL ASSETS	12,076.56	10,756.19
II. EQUITY AND LIABILITIES		
A Equity		
a. Equity Share Capital	826.37	826.37
b. Other Equity	9,042.02	7,798.04
TOTAL EQUITY	9,868.39	8,624.41
B Liabilities		
1. Non-Current Liabilities		
a. Financial Liabilities		
(i) Borrowings	161.18	108.11
(ii) Lease liabilities	108.68	110.86
b. Deferred tax liabilities (Net)	125.79	127.55
c. Provisions	153.77	143.27
Total Non-Current Liabilities	549.42	489.79
2. Current Liabilities		
a. Financial Liabilities		
(i) Borrowings	446.91	645.01
(ii) Lease liabilities	16.66	28.97
(iii) Trade payables	535.64	415.99
(iv) Other financial liabilities	260.90	317.29
b. Other current liabilities	260.37	174.83
c. Provisions	31.14	28.51
d. Current Tax Liabilities (Net)	107.13	31.39
Total Current Liabilities	1,658.75	1,641.99
TOTAL EQUITY AND LIABILITIES	12,076.56	10,756.19

For Titan Biotech Limited


[Naresh Kumar Singla]
Managing Director
DIN-00027448



Place : Delhi
Date : 14.11.2022

TITAN BIOTECH LIMITED		
Standalone Cash Flow Statement for the period ended on 30th September, 2022		
	(Rs. in Lakhs.)	
Particulars	Period ended	Year ended
	30/09/2022	31/03/2022
	Unaudited	Audited
A. CASH FLOW FROM OPERATING ACTIVITIES		
Profit before Tax	1,813.22	2,896.90
Adjustment for :	-	-
Finance Costs	34.62	78.39
Provisions	13.12	27.87
Earlier year Taxes	3.43	0.03
Depreciation and Amortization Expenses	124.21	236.91
Operating profit before working capital changes	1,988.60	3,240.10
Changes in working Capital:		
Inventories	(512.14)	(785.15)
Trade and other Receivables	(546.09)	203.24
Trade and other Payables	148.80	248.83
Cash generation from Operation	1,079.17	2,907.02
Payment of Direct Taxes	(374.74)	(711.77)
Net Cash generated/ (used) - Operating Activities	704.43	2,195.25
B. CASH FLOW FROM INVESTMENT ACTIVITIES		
Purchase of Investment in shares	(275.63)	(275.63)
Purchase of Fixed Assets (incl.Capital WIP)	(464.77)	(631.12)
Right of use assets	19.70	(736.90)
Net Cash Generated/ (Used) - Investing Activities	(720.70)	(1,643.65)
C.CASH FLOW FROM FINANCING ACTIVITIES		
Repayment of Long-term Borrowings	53.07	(74.58)
Repayment of Lease Liabilities	(14.48)	(25.02)
Proceeds/(Repayment) of Short-term Borrowings (Net)	(198.10)	(99.12)
Finance Cost paid	(34.62)	(78.39)
Dividend paid	(123.96)	(123.96)
Net Cash Generated/ (Used) - Financing Activities	(318.09)	(401.07)
Net Increase/ (Decrease) in Cash and Cash Equivalents	(334.36)	150.53
Add : Opening Cash and Cash Equivalents	681.39	530.86
Closing Cash and Cash Equivalents	347.03	681.39
Notes:		
1. The Cash Flow Statements have been prepared under the indirect method as set out in Accounting Standard (AS) on Statement of Cash Flow (Ind AS-7).		
2. Figures in bracket represent outflows.		
3. Previous year's figures have been regrouped wherever considered necessary to conform to this year's classification.		
<div style="display: flex; justify-content: space-between; align-items: flex-end;"> <div> <p>Place : Delhi</p> <p>Date : 14.11.2022</p> </div> <div style="text-align: right;"> <p>For Titan Biotech Limited</p>  <p>[Naresh Kumar Singla] Managing Director DIN-00027448</p> </div> <div style="text-align: right;">  </div> </div>		

TITAN BIOTECH LIMITED

Regd. Office :- A-902 A, RIICO Industrial Area, Phase III, Bhiwadi, Rajasthan-301019

Phone No. 011- 71239900, Email : hrd@titanbiotechltd.com www.titanbiotechltd.com CIN : L74999RJ1992PLC013387

STATEMENT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND SIX MONTHS ENDED ON 30TH SEPTEMBER, 2022

(Rs. IN LAKHS) except for EPS


Sr. No	PARTICULARS	CONSOLIDATED					
		QUARTER ENDED			SIX MONTHS ENDED		YEAR ENDED
		30.09.2022	30.06.2022	30.09.2021	30.09.2022	30.09.2021	31.03.2022
		UNAUDITED	UNAUDITED	UNAUDITED	UNAUDITED	UNAUDITED	AUDITED
1	INCOME						
	Revenue from operations	4,183.38	3,499.62	4,200.72	7,683.00	8,344.69	15,280.97
	Other Income	85.64	31.64	25.66	117.28	40.01	102.25
	Total Income	4,269.02	3,531.26	4,226.38	7,800.28	8,384.70	15,383.22
2	EXPENSES						
	Cost of Materials Consumed	2,178.59	1,784.39	2,143.25	3,962.98	4,099.15	7,547.79
	Changes in Inventories of Finished Goods, Stock-in-Trade and Work-in-Progress	(44.93)	(60.73)	45.68	(105.66)	21.81	(60.16)
	Employee Benefit Expenses	452.21	379.95	399.07	832.16	764.27	1,613.74
	Finance Costs	17.03	17.59	36.37	34.62	73.90	128.26
	Depreciation and Amortization Expenses	63.76	60.45	62.45	124.21	120.85	253.84
	Other Expenses	549.38	589.37	565.08	1,138.75	971.08	2,079.92
	Total Expenses	3,216.04	2,771.02	3,251.90	5,987.06	6,051.06	11,563.39
3	Profit/(Loss) before exceptional items and tax (1-2)	1,052.98	760.24	974.48	1,813.22	2,333.64	3,819.83
4	Exceptional Items	-	-	-	-	-	-
5	Profit/ (loss) before tax (3+4)	1,052.98	760.24	974.48	1,813.22	2,333.64	3,819.83
6	Tax expense:						
	I) Current Tax	268.61	181.86	212.03	450.47	583.80	970.33
	II) Earlier year taxes	(1.76)	-	0.24	(1.76)	0.24	1.69
	III) Deferred Tax	(4.08)	0.65	1.34	(3.43)	3.15	(7.50)
	Total Tax (I+II)	262.77	182.51	213.61	445.28	587.19	964.52
7	Profit (Loss) for the period after Tax (5-6)	790.21	577.73	760.87	1,367.94	1,746.45	2,855.31
8	Share in Profit of Associate	122.48	172.72	-	295.20	-	19.03
9	Profit (Loss) for the period (7+8)	912.69	750.45	760.87	1,663.14	1,746.45	2,874.34
10	other comprehensive income (Net of Tax)						
A.	Items that will not be reclassified to profit or loss						
	Re-measurement gain on defined benefit plans	-	-	-	-	-	(2.08)
(i)	Items that will be reclassified to profit or loss	-	-	-	-	-	-
B	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
	Total Other Comprehensive Income for the period (A+B)(net of taxes)	-	-	-	-	-	(2.08)
11	Total Comprehensive Income for the period (7+8)	912.69	750.45	760.87	1,663.14	1,746.45	2,872.26
12	Net profit attributable to:						
	Owners of the holding company	-	-	639.23	-	1,511.55	2,533.30
	Non-controlling interest	-	-	121.64	-	234.90	322.01
13	Other comprehensive income attributable to :						
	Owners of the holding company	-	-	-	-	-	(1.71)
	Non-controlling interest	-	-	-	-	-	(0.37)
14	Total Comprehensive Income attributable to (10+11)						
	Owners of the holding company	-	-	639.23	-	1,511.55	2,531.59
	Non-controlling interest	-	-	121.64	-	234.90	321.64
15	Paid-up equity share capital (Face Value of Rs. 10/- each)	826.37	826.37	826.37	826.37	826.37	826.37
16	Other Equity	-	-	-	-	-	9,040.49
17	Earnings per equity share (face value of Rs.10/- each) not annualised						
	(1) Basic	11.04	9.08	7.74	20.13	18.29	30.66
	(2) Diluted	11.04	9.08	7.74	20.13	18.29	30.66

Notes:

- The above consolidated unaudited financial results for the quarter and six months ended on 30.09.2022 have been reviewed by the Audit Committee and taken on record by the Board of Directors of the Company at their respective meeting held on November 14, 2022. The statutory auditors of the company have carried out a limited review of the aforesaid results. The results for the quarter and six months ended Sept. 30, 2022, are available on the BSE Limited website(bseindia.com) and on the company's Website(titanbiotechltd.com)
- The consolidated unaudited financial results for the quarter and six months ended on 30.09.2022 include the results of following:-
Associate Company - Peptech Biosciences Limited
- The Company has elected to exercise the option permitted under section 115BAA of the Income Tax Act, 1961 as introduced by Taxation Law(Amendment) Ordinance 2019. Accordingly, the Company has recognized provision for income tax for the quarter and six months ended on 30 Sept. 2022 and remeasured its deferred tax balance on the basis of the rate prescribed in the said section.
- The total sale for the quarter ended 30.09.2022 includes sale of Products of Rs. 11.29 Lakhs the demand for which arose due to Covid 19 Pandemic.
- Previous period figures are regrouped/reclassified in line with the current period.
- The Company has only one reportable business segment.
- The consolidated unaudited financial results have been prepared in accordance with the Indian Accounting Standards ("Ind AS") specified in the Companies (Indian Accounting Standards) Rules 2015 (as amended) under section 133 of the Companies Act 2013 (the "accounting principles generally accepted in India").
- Freight amount has been added in revenue from operation for the purpose of calculation of sales including GST in current year. Freight also added in total in other expenses to neutralise the impact of its addition in revenue in current year.

For and on behalf of Board of Directors
for TITAN BIOTECH LIMITED

NARESH KUMAR SINGLA
Managing Director
DIN-00027448



Place : Delhi
Dated : 14.11.2022

TITAN BIOTECH LIMITED

Regd. Office :- A-902 A RIICO Industrial Area, Phase III, Bhiwadi, Rajasthan-301019

Phone No. 011-71239900, Email : hrd@titanbiotechltd.com www.titanbiotechltd.com CIN : L74999RJ1992PLC013387

STATEMENT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND SIX MONTHS ENDED ON 30TH SEPTEMBER, 2022

(Rs. IN LAKHS) except for EPS


S.NO.	PARTICULARS	CONSOLIDATED					
		QUARTER ENDED			SIX MONTHS ENDED		YEAR ENDED
		30.09.2022 UNAUDITED	30.06.2022 UNAUDITED	30.09.2021 UNAUDITED	30.09.2022 UNAUDITED	30.09.2021 UNAUDITED	31.03.2022 AUDITED
1	Total Income from Operations (Net)	4,269.02	3,531.26	4,226.38	7,800.28	8,384.70	15,383.22
2	Net Profit/(Loss) for the period (before tax, exceptional and/or extraordinary items)	1,052.98	760.24	974.48	1,813.22	2,333.64	3,819.83
3	Net Profit/(Loss) for the period before tax (after exceptional and/or extraordinary items)	1,052.98	760.24	974.48	1,813.22	2,333.64	3,819.83
4	Net Profit/(Loss) for the period after tax (after exceptional and/or extraordinary items)	912.69	750.45	760.87	1,367.94	1,746.45	2,874.34
5	Total comprehensive income for the period (comprising Profit/(Loss) for the period (after tax) and Other Comprehensive income (after tax) (refer note 3)	912.69	750.45	760.87	1,663.14	1,746.45	2,872.26
6	Paid-up Equity Share Capital (Face value of Rs. 10/- per share)	826.37	826.37	826.37	826.37	826.37	826.37
7	Other Equity excluding Revaluation Reserves as per the balance sheet						
8	Earning Per Share (of INR 10/- each)						
	(a) Basic	11.04	9.08	7.74	20.13	18.29	30.66
	(b) Diluted	11.04	9.08	7.74	20.13	18.29	30.66

NOTES :

- The above is an extract of the detailed format of consolidated Unaudited Financial Results for the quarter and six months ended on 30.09.2022 filed with the BSE Limited Under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the consolidated unaudited Financial Results for the said quarter and six months ended on 30th Sept 2022 are available on the website of BSE Limited at www.bseindia.com and on company website at www.titanbiotechltd.com.
- The above consolidated unaudited financial results for the quarter and six months ended on 30.09.2022 have been reviewed by the Audit Committee and taken on record by the Board of Directors of the Company at their respective meeting held on November 14, 2022. The Statutory Auditors of the Company have carried out a Limited Review of the aforesaid results.
- The Company has elected to exercise the option permitted under section 115BAA of the Income Tax Act, 1961 as introduced by Taxation Law (Amendment) Ordinance 2019. Accordingly, the Company has recognized provision for income tax for the quarter and six months ended on 30.09.2022 and remeasured its deferred tax balance on the basis of the rate prescribed in the said section.
- The total sale for the quarter ended 30.09.2022 includes sale of Products of Rs. 11.29 Lakhs the demand for which arose due to Covid 19 Pandemic.
- The consolidated unaudited financial results have been prepared in accordance with the Indian Accounting Standards ('Ind AS') specified in the Companies (Indian Accounting Standards) Rules 2015 (as amended) under section 133 of the Companies Act 2013 (the "accounting principles generally accepted in India").
- Freight amount has been added in revenue from operation for the purpose of calculation of sales including GST in current year. Freight also added in total in other expenses to neutralise the impact of its addition in revenue in current year.

For and on behalf of Board of Directors
for TITAN BIOTECH LIMITED

NARESH KUMAR SINGLA
Managing Director
DIN-00027448




Place : Delhi
Dated : 14.11.2022

TITAN BIOTECH LIMITED
Consolidated Balance Sheet as at 30th September, 2022


(Rs. in Lakhs.)



Particulars	As at	
	30/09/2022 Unaudited	31/03/2022 Audited
I ASSETS		
1. Non-Current Assets		
a. Property, Plant and Equipment	2,557.35	2,695.68
b. Capital Work-in-Progress	701.35	796.63
c. Right of use Assets	914.14	1,509.60
d. Intangible assets	9.92	10.45
e. Other Non Current Assets	-	11.40
f. Financial Assets		
(i) Investments	973.95	-
(ii) Other Financial Assets	169.69	181.40
Total Non-current assets	5,326.40	5,205.16
2. Current Assets		
a. Inventories	3,980.12	4,229.46
b. Financial Assets	-	-
(i) Trade receivables	2,534.45	2,167.08
(ii) Cash and cash equivalents	347.03	1,560.67
c. Current Tax Assets (Net)	-	-
d. Other Current Assets	183.76	1,177.51
Total Current assets	7,045.36	9,134.72
TOTAL ASSETS	12,371.76	14,339.88
II. EQUITY AND LIABILITIES		
A Equity		
a. Equity Share Capital	826.37	826.37
b. Other Equity	9,337.22	9,040.49
c. Non Controlling Interest	-	674.39
TOTAL EQUITY	10,163.59	10,541.25
B Liabilities		
1. Non-Current Liabilities		
a. Financial Liabilities		
(i) Borrowings	161.18	839.84
(ii) Lease liabilities	108.68	154.72
b. Deferred tax liabilities (Net)	125.79	130.73
c. Provisions	153.77	150.50
Total Non-Current Liabilities	549.42	1,275.79
2. Current Liabilities		
a. Financial Liabilities		
(i) Borrowings	446.91	747.00
(ii) Lease liabilities	16.66	33.37
(iii) Trade payables	535.64	754.79
(iv) Other Financial Liabilities	260.90	615.75
b. Other current liabilities	260.37	217.41
c. Provisions	31.14	28.87
d. Current Tax Liabilities (Net)	107.13	125.65
Total Current Liabilities	1,658.75	2,522.84
TOTAL EQUITY AND LIABILITIES	12,371.76	14,339.88

For Titan Biotech Limited


 [Naresh Kumar Singla]
 Managing Director
 DIN-00027448

Place : Delhi
 Date : 14.11.2022



TITAN BIOTECH LIMITED Consolidated Cash Flow Statement for the period ended on 30th September, 2022 (Rs. in Lakhs.)		
Particulars	Period ended	Year ended
	30/09/2022 Unaudited	31/03/2022 Audited
A. CASH FLOW FROM OPERATING ACTIVITIES		
Profit before Tax	1,813.22	3,819.83
Adjustment for :	-	-
Finance Costs	34.62	128.26
Earlier year Taxes	3.43	(1.69)
Provision for employees Benefits	13.12	27.87
Depreciation and Amortization Expenses	124.21	253.84
Operating profit before working capital changes	1,988.60	4,228.11
Changes in working Capital:		
Inventories	(512.14)	(975.67)
Trade and other Receivables	(546.09)	(652.37)
Trade and other Payables	148.80	566.24
Cash generation from Operation	1,079.17	3,166.31
Payment of Direct Taxes	(374.74)	(880.39)
Net Cash generated/ (used) - Operating Activities	704.43	2,285.92
B. CASH FLOW FROM INVESTMENT ACTIVITIES		
Purchase of Fixed Assets (incl.Capital WIP and Right of use assets)	(464.77)	(1,099.49)
Right of use assets	19.70	(779.01)
Purchase of Investments	(275.63)	-
Net Cash Generated/ (Used) - Investing Activities	(720.70)	(1,878.50)
C.CASH FLOW FROM FINANCING ACTIVITIES		
Repayment of Long-term Borrowings	53.07	272.79
Repayment of Lease Liabilities	(14.48)	23.25
Proceeds/(Rapyment)of Short-term Borrowings(Net)	(198.10)	-
Share application pending for allotment	-	564.37
Finance Cost paid	(34.62)	(128.26)
Dividend paid	(123.96)	(123.96)
Net Cash Generated/ (Used) - Financing Activities	(318.09)	608.19
Net Increase/ (Decrease) in Cash and Cash Equivalents	(334.36)	1,015.61
Add : Opening Cash and Cash Equivalents	681.39	545.06
Closing Cash and Cash Equivalents	347.03	1,560.67
Notes: 1. The Cash Flow Statements have been prepared under the indirect method as set out in Accounting Standard (AS) on Statement of Cash Flow (Ind AS-7). 2. Figures in bracket represent outflows. 3. Previous year's figures have been regrouped wherever considered necessary to conform to this year's classification.		
<div style="display: flex; justify-content: space-between; align-items: flex-end;"> <div> Place : Delhi Date : 14.11.2022 </div> <div style="text-align: center;"> For Titan Biotech Limited  [Naresh Kumar Singla] Managing Director DIN-00027448 </div> <div style="text-align: right;">  </div> </div>		